Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Tonix Pharmaceuticals
Tonix PharmaceuticalsBERKELEY HEIGHTS, NJ
1 program
1
TNX-102 SLPhase 21 trial
Active Trials
NCT05472090Completed63Est. Jul 2023

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Tonix PharmaceuticalsTNX-102 SL

Clinical Trials (1)

Total enrollment: 63 patients across 1 trials

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

Start: Aug 2022Est. completion: Jul 202363 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space